Halla Thorsteinsdóttir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Halla Thorsteinsdóttir has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Abdallah S Daar
University of Toronto Joint Centre for Bioethics
7 shared publicationsUyen Quach
7 shared publicationsPeter A Singer
University of Toronto Joint Centre for Bioethics
6 shared publicationsAbdallah S. Daar
Dalla Lana School of Public Health
2 shared publicationsDouglas K Martin
University of Toronto
2 shared publicationsMonali Ray
University of Toronto
2 shared publications
Latest Publications
- Open Access
- 21 February 2017
- Published by Springer Nature in Globalization and Health
- Vol. 13 (1) , 10
Corporate social responsibility to improve access to medicines: the case of Brazil
Access to medicines and the development of a strong national pharmaceutical industry are two longstanding pillars of health policy in Brazil. This is reflected in a clear emphasis by Brazil’s Federal Government on improving access to medicine in national health plans and industrial policies aimed at promoting domestic pharmaceutical development. This research proposes that such policies may act as incentives for companies to pursue a strategic Corporate Social Responsibility (CSR) agenda. CSR that supports Governmental priorities could help companies to benefit significantly from the Governmental industrial policy. We sought to determine whether CSR activities of Brazilian pharmaceutical firms are currently aligned with the Federal Government’s health prioritization. To do so we examined key Brazilian health related policies since 2004, including the specific priorities of Brazil’s 2012–2015 Health Plan, and compared these with CSR initiatives that are reported on the websites of select pharmaceutical firms in Brazil. Brazil’s national health plans and industrial policies demonstrated that the Federal Government has followed diverse approaches for improving access to medicines, including strengthening health care infrastructure, increasing transparency, and supporting product development partnerships. Case studies of six pharmaceutical firms, representing both public and private companies of varying size, support the perspective that CSR is a priority for firms. However, while many programs target issues such as health infrastructure, health care training, and drug donation, more programs focus on areas other than health and do not seem to be connected to Governmental prioritization. This research suggests that there are loose connections between Governmental priorities and pharmaceutical firm CSR. However, there remains a significant opportunity for greater alignment, which could improve access to medicines in the country and foster a stronger relationship between the Government and industry.
- 21 February 2017
- Published by Springer Nature in Globalization and Health
- Vol. 13 (1) , 10
Open AccessCorporate social responsibility to improve access to medicines: the case of Brazil
Access to medicines and the development of a strong national pharmaceutical industry are two longstanding pillars of health policy in Brazil. This is reflected in a clear emphasis by Brazil’s Federal Government on improving access to medicine in national health plans and industrial policies aimed at promoting domestic pharmaceutical development. This research proposes that such policies may act as incentives for companies to pursue a strategic Corporate Social Responsibility (CSR) agenda. CSR that supports Governmental priorities could help companies to benefit significantly from the Governmental industrial policy. We sought to determine whether CSR activities of Brazilian pharmaceutical firms are currently aligned with the Federal Government’s health prioritization. To do so we examined key Brazilian health related policies since 2004, including the specific priorities of Brazil’s 2012–2015 Health Plan, and compared these with CSR initiatives that are reported on the websites of select pharmaceutical firms in Brazil. Brazil’s national health plans and industrial policies demonstrated that the Federal Government has followed diverse approaches for improving access to medicines, including strengthening health care infrastructure, increasing transparency, and supporting product development partnerships. Case studies of six pharmaceutical firms, representing both public and private companies of varying size, support the perspective that CSR is a priority for firms. However, while many programs target issues such as health infrastructure, health care training, and drug donation, more programs focus on areas other than health and do not seem to be connected to Governmental prioritization. This research suggests that there are loose connections between Governmental priorities and pharmaceutical firm CSR. However, there remains a significant opportunity for greater alignment, which could improve access to medicines in the country and foster a stronger relationship between the Government and industry.
- 1 February 2017
- Published by Elsevier in Technology in Society
- Vol. 48, 1-10
Some factors limiting transfer of biotechnology research for health care at Cinvestav: A Mexican scientific center
- 1 February 2017
- Published by Elsevier in Technology in Society
- Vol. 48, 1-10
Some factors limiting transfer of biotechnology research for health care at Cinvestav: A Mexican scientific center
- 5 January 2012
- Published by Elsevier in Health Policy
- Vol. 105 (2-3) , 226-235
Stakeholder involvement in expensive drug recommendation decisions: An international perspective
- 5 January 2012
- Published by Elsevier in Health Policy
- Vol. 105 (2-3) , 226-235
Stakeholder involvement in expensive drug recommendation decisions: An international perspective
- 1 December 2011
- Published by Oxford University Press (OUP) in Science and Public Policy
- Vol. 38 (10) , 767-781
Developing biomedical innovation capacity in India
This paper charts the process through which India developed increasingly cutting edge capacity in biomedicine by incrementally ‘building on’ existing, more established areas of its biomedical technological system. It examines the development of India's pharmaceutical sector, explores how Indian biotechnology built on its existing pharmaceutical capacity, and analyses whether India's regenerative medicine sector is using capacities developed in both India's pharmaceutical and biotechnology sectors. We draw on previous studies of India's pharmaceutical and biotechnology sectors as well as our own regenerative medicine case study. In charting this evolution, we gain insight into how developing economies build capacity by relying on existing expertise and then move into frontier areas within a technological system.
- 1 December 2011
- Published by Oxford University Press (OUP) in Science and Public Policy
- Vol. 38 (10) , 767-781
Developing biomedical innovation capacity in India
This paper charts the process through which India developed increasingly cutting edge capacity in biomedicine by incrementally ‘building on’ existing, more established areas of its biomedical technological system. It examines the development of India's pharmaceutical sector, explores how Indian biotechnology built on its existing pharmaceutical capacity, and analyses whether India's regenerative medicine sector is using capacities developed in both India's pharmaceutical and biotechnology sectors. We draw on previous studies of India's pharmaceutical and biotechnology sectors as well as our own regenerative medicine case study. In charting this evolution, we gain insight into how developing economies build capacity by relying on existing expertise and then move into frontier areas within a technological system.
- 13 January 2011
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 9 (2) , 137-143
Health biotechnology innovation on a global stage
With increasing globalization, infectious diseases are spreading faster than ever before, creating an urgent need for international collaboration. The rise of emerging economies has changed the traditional collaborative landscape and provided opportunities for more diverse models of collaboration involving developing countries, including North-South, South-South and North-South-South partnerships. Here, we discuss how developing countries can partner with other nations to address their shared health problems and to promote innovation. We look specifically at what drives collaborations and at the challenges that exist for them, and we propose actions that can strengthen these partnerships.
- 13 January 2011
- Published by Springer Nature in Nature Reviews Microbiology
- Vol. 9 (2) , 137-143
Health biotechnology innovation on a global stage
With increasing globalization, infectious diseases are spreading faster than ever before, creating an urgent need for international collaboration. The rise of emerging economies has changed the traditional collaborative landscape and provided opportunities for more diverse models of collaboration involving developing countries, including North-South, South-South and North-South-South partnerships. Here, we discuss how developing countries can partner with other nations to address their shared health problems and to promote innovation. We look specifically at what drives collaborations and at the challenges that exist for them, and we propose actions that can strengthen these partnerships.
- 1 July 2010
- Vol. 12 (3) , 32-5
Cuba and Brazil: an important example of South-South collaboration in health biotechnology.
This article analyzes the entrepreneurial cooperation between Cuba and Brazil in health biotechnology. It looks at the strategies applied and the main impacts. The respective government/political wills and the corresponding South-South collaboration policies are discussed, as well as the steps taken to materialize collaboration programs, including joint production of a meningitis vaccine for Africa. This cooperation is a good example of how South-South collaboration can be a useful tool to promote capacity building and provide cost-effective health solutions for developing countries.
- 1 July 2010
- Vol. 12 (3) , 32-5
Cuba and Brazil: an important example of South-South collaboration in health biotechnology.
This article analyzes the entrepreneurial cooperation between Cuba and Brazil in health biotechnology. It looks at the strategies applied and the main impacts. The respective government/political wills and the corresponding South-South collaboration policies are discussed, as well as the steps taken to materialize collaboration programs, including joint production of a meningitis vaccine for Africa. This cooperation is a good example of how South-South collaboration can be a useful tool to promote capacity building and provide cost-effective health solutions for developing countries.
- 1 March 2009
- Published by Springer Nature in Nature Biotechnology
- Vol. 27 (3) , 229-232
A survey of South-North health biotech collaboration
- 1 March 2009
- Published by Springer Nature in Nature Biotechnology
- Vol. 27 (3) , 229-232
A survey of South-North health biotech collaboration
- 6 September 2007
- Published by Taylor & Francis in Technology Analysis & Strategic Management
- Vol. 19 (5) , 659-675
The Role of the Health System in Health Biotechnology in Developing Countries
This paper examines the role of local health systems in developing countries in health biotechnology innovation. The heath systems encompass the final users of health biotechnology products and services. In innovation studies in general, users have been identified as playing vital roles as sources for innovation and in shaping the innovation process. It is therefore of interest to cast light upon the role of users in the health biotechnology innovation in developing countries. This paper briefly reviews literature on science and technology based health innovation in both industrialised and developing countries. It then examines to what extent the focus of developing countries is on their local health problems and explores the linkages between the organisations involved in research and development of health biotechnology products and services with the local health system, and thereby identifies the main roles of their own health systems in the innovation process. The paper bases this analysis on research on publication patterns and case studies on leading developing countries in health biotechnology and focuses particularly on health biotechnology development in Brazil, Cuba and India.
- 6 September 2007
- Published by Taylor & Francis in Technology Analysis & Strategic Management
- Vol. 19 (5) , 659-675
The Role of the Health System in Health Biotechnology in Developing Countries
This paper examines the role of local health systems in developing countries in health biotechnology innovation. The heath systems encompass the final users of health biotechnology products and services. In innovation studies in general, users have been identified as playing vital roles as sources for innovation and in shaping the innovation process. It is therefore of interest to cast light upon the role of users in the health biotechnology innovation in developing countries. This paper briefly reviews literature on science and technology based health innovation in both industrialised and developing countries. It then examines to what extent the focus of developing countries is on their local health problems and explores the linkages between the organisations involved in research and development of health biotechnology products and services with the local health system, and thereby identifies the main roles of their own health systems in the innovation process. The paper bases this analysis on research on publication patterns and case studies on leading developing countries in health biotechnology and focuses particularly on health biotechnology development in Brazil, Cuba and India.
- 1 March 2006
- Published by Springer Nature in Nature Biotechnology
- Vol. 24 (3) , 309
Off the beaten path
- 1 March 2006
- Published by Springer Nature in Nature Biotechnology
- Vol. 24 (3) , 309
Off the beaten path